


We claim:

1. A compound of Formula I:



wherein:

5 n is an integer of 1,2, or 3;

R^A is $-\text{CONHR}^1$, $-\text{NHR}^1$, $-\text{NHCOR}^1$, $-\text{NHCONHR}^1$, $-\text{NHCO}_2\text{R}^1$, $-\text{NHSO}_2\text{R}^1$ or $-\text{NHSO}_2\text{NHR}^1$;

wherein R^1 is hydrogen or an optionally substituted C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryl, C_3 - C_7 cycloalkyl, heteroaryl, heterocyclyl, aryl- C_1 - C_4 alkyl- or
 10 heteroaryl- C_1 - C_4 alkyl- group,

where said optionally substituted R^1 group is optionally substituted with one or more substituents independently selected from halogen, $-\text{R}^{1a}$, $-\text{OR}^{1a}$, $-\text{SR}^{1a}$, $-\text{SO}_2\text{R}^{1c}$, $-\text{NR}^{1a}\text{R}^{1b}$, cyano, nitro, $-\text{COR}^{1c}$, $-\text{CO}_2\text{R}^{1a}$, $-\text{NR}^{1b}\text{COR}^{1a}$, $-\text{CONR}^{1a}\text{R}^{1b}$, $-\text{NR}^{1b}\text{SO}_2\text{R}^{1c}$, and $-\text{SO}_2\text{NR}^{1a}\text{R}^{1b}$,

15 where R^{1a} is hydrogen or an optionally substituted C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryl, C_3 - C_7 cycloalkyl, heteroaryl, heterocyclyl, aryl- C_1 - C_4 alkyl-, C_3 - C_7 cycloalkyl- C_1 - C_4 alkyl-, heteroaryl- C_1 - C_4 alkyl-, heterocyclyl- C_1 - C_4 alkyl-, aryl- C_2 - C_4 alkenyl-, C_3 - C_7 cycloalkyl- C_2 - C_4 alkenyl-, heteroaryl- C_2 - C_4 alkenyl-, heterocyclyl- C_2 - C_4 alkenyl-, aryl- C_2 - C_4 alkynyl-, C_3 - C_7 cycloalkyl- C_2 - C_4 alkynyl-,
 20 heteroaryl- C_2 - C_4 alkynyl-, or heterocyclyl- C_2 - C_4 alkynyl- group,

R^{1b} is hydrogen or unsubstituted C_1 - C_4 alkyl, and

R^{1c} is an optionally substituted C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryl, C_3 - C_7 cycloalkyl, heteroaryl, heterocyclyl, aryl- C_1 - C_4 alkyl-, C_3 - C_7 cycloalkyl- C_1 - C_4 alkyl-, heteroaryl- C_1 - C_4 alkyl-, heterocyclyl- C_1 - C_4 alkyl-, aryl- C_2 - C_4 alkenyl-,
 25 C_3 - C_7 cycloalkyl- C_2 - C_4 alkenyl-, heteroaryl- C_2 - C_4 alkenyl-, heterocyclyl- C_2 - C_4 alkenyl-, aryl- C_2 - C_4 alkynyl-, C_3 - C_7 cycloalkyl- C_2 - C_4 alkynyl-, heteroaryl- C_2 - C_4 alkynyl-, or heterocyclyl- C_2 - C_4 alkynyl- group,

where each optionally substituted R^{1a} group and R^{1c} group is independently optionally substituted with one or more substituents independently selected from

C₁-C₄ alkyl, C₁-C₄ haloalkyl, -OC₁-C₄ alkyl, -OC₁-C₄ haloalkyl, halogen, -OH, -NH₂,
 -N(C₁-C₄ alkyl)(C₁-C₄ alkyl), -NH(C₁-C₄ alkyl), cyano, nitro, oxo, -CO₂H,
 -C(O)OC₁-C₄ alkyl, -CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CONH₂,
 -NHC(O)(C₁-C₄ alkyl), -C(O)C₁-C₄ alkyl, -C(O)C₁-C₄ haloalkyl, -OC(O)C₁-C₄ alkyl,
 5 -OC(O)C₁-C₄ haloalkyl, -SO₂(C₁-C₄ alkyl), -SO₂(C₁-C₄ haloalkyl), -SO₂NH₂, -
 SO₂NH(C₁-C₄ alkyl), -NHS(O)₂(C₁-C₄ alkyl), and -NHS(O)₂(C₁-C₄ haloalkyl), where said
 C₁-C₄ alkyl is unsubstituted C₁-C₄ alkyl,

or R^{1a} and R^{1b}, together with the nitrogen atom to which they are attached, form an
 optionally substituted heterocycyl or heteroaryl ring which optionally contains one or more
 10 additional heteroatom moieties selected from O, S, SO, SO₂, N and N→O, wherein said
 optionally substituted heterocycyl or heteroaryl ring is optionally substituted with one or
 more substituents independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, -OC₁-C₄ alkyl,
 -OC₁-C₄ haloalkyl, halogen, -OH, -NH₂, -N(C₁-C₄ alkyl)(C₁-C₄ alkyl), -NH(C₁-C₄ alkyl),
 cyano, nitro, oxo, -CO₂H, -C(O)OC₁-C₄ alkyl, -CON(C₁-C₄ alkyl)(C₁-C₄ alkyl),
 15 -CONH(C₁-C₄ alkyl), -CONH₂, -NHC(O)(C₁-C₄ alkyl), -C(O)C₁-C₄ alkyl,
 -C(O)C₁-C₄ haloalkyl, -OC(O)C₁-C₄ alkyl, -OC(O)C₁-C₄ haloalkyl, -SO₂(C₁-C₄ alkyl), -
 SO₂(C₁-C₄ haloalkyl), -SO₂NH₂, -SO₂NH(C₁-C₄ alkyl), -NHS(O)₂(C₁-C₄ alkyl), and
 -NHS(O)₂(C₁-C₄ haloalkyl), where said C₁-C₄ alkyl is unsubstituted C₁-C₄ alkyl,

X is NR², O, S, SO or SO₂,

20 wherein R² is hydrogen or an optionally substituted C₁-C₆ alkyl, C₂-C₆ alkenyl,
 C₂-C₆ alkynyl, aryl, C₃-C₇ cycloalkyl, heteroaryl, heterocyclyl, aryl-C₁-C₄ alkyl- or
 heteroaryl-C₁-C₄ alkyl- group,

where said optionally substituted R² group is optionally substituted with one or
 more substituents independently selected from halogen, -R^{2a}, -OR^{2a}, -SR^{2a}, -SO₂R^{2c}
 25 -NR^{2a}R^{2b}, cyano, nitro, -COR^{2c}, -CO₂R^{2a}, -NR^{2b}COR^{2a}, -CONR^{2a}R^{2b}, -NR^{2b}SO₂R^{2c}, and
 -SO₂NR^{2a}R^{2b},

where R^{2a} is hydrogen or an optionally substituted C₁-C₆ alkyl, C₂-C₆ alkenyl,
 C₂-C₆ alkynyl, aryl, C₃-C₇ cycloalkyl, heteroaryl, heterocyclyl, aryl-C₁-C₄ alkyl-
 C₃-C₇ cycloalkyl-C₁-C₄ alkyl-, heteroaryl-C₁-C₄ alkyl-, heterocycyl-C₁-C₄ alkyl-,
 30 aryl-C₂-C₄ alkenyl-, C₃-C₇ cycloalkyl-C₂-C₄ alkenyl-, heteroaryl-C₂-C₄ alkenyl-,
 heterocycyl-C₂-C₄ alkenyl-, aryl-C₂-C₄ alkynyl-, C₃-C₇ cycloalkyl-C₂-C₄ alkynyl-,
 heteroaryl-C₂-C₄ alkynyl-, or heterocycyl-C₂-C₄ alkynyl- group,

R^{2b} is hydrogen or unsubstituted C₁-C₄ alkyl, and

R^{2c} is an optionally substituted C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, C_3-C_7 cycloalkyl, heteroaryl, heterocyclyl, aryl- C_1-C_4 alkyl-, C_3-C_7 cycloalkyl- C_1-C_4 alkyl-, heteroaryl- C_1-C_4 alkyl-, heterocyclyl- C_1-C_4 alkyl-, aryl- C_2-C_4 alkenyl-, C_3-C_7 cycloalkyl- C_2-C_4 alkenyl-, heteroaryl- C_2-C_4 alkenyl-, heterocyclyl- C_2-C_4 alkenyl-, aryl- C_2-C_4 alkynyl-, C_3-C_7 cycloalkyl- C_2-C_4 alkynyl-, heteroaryl- C_2-C_4 alkynyl-, or heterocyclyl- C_2-C_4 alkynyl- group,

where each optionally substituted R^{2a} group and R^{2c} group is independently optionally substituted with one or more substituents independently selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, $-OC_1-C_4$ alkyl, $-OC_1-C_4$ haloalkyl, halogen, $-OH$, $-NH_2$, $-N(C_1-C_4 \text{ alkyl})(C_1-C_4 \text{ alkyl})$, $-NH(C_1-C_4 \text{ alkyl})$, cyano, nitro, oxo, $-CO_2H$, $-C(O)OC_1-C_4$ alkyl, $-CON(C_1-C_4 \text{ alkyl})(C_1-C_4 \text{ alkyl})$, $-CONH(C_1-C_4 \text{ alkyl})$, $-CONH_2$, $-NHC(O)(C_1-C_4 \text{ alkyl})$, $-C(O)C_1-C_4$ alkyl, $-C(O)C_1-C_4$ haloalkyl, $-OC(O)C_1-C_4$ alkyl, $-OC(O)C_1-C_4$ haloalkyl, $-SO_2(C_1-C_4 \text{ alkyl})$, $-SO_2(C_1-C_4 \text{ haloalkyl})$, $-SO_2NH_2$, $-SO_2NH(C_1-C_4 \text{ alkyl})$, $-NHS(O)_2(C_1-C_4 \text{ alkyl})$, and $-NHS(O)_2(C_1-C_4 \text{ haloalkyl})$, where said C_1-C_4 alkyl is unsubstituted C_1-C_4 alkyl,

or R^{2a} and R^{2b} , together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclyl or heteroaryl ring which optionally contains one or more additional heteroatom moieties selected from O, S, SO, SO_2 , N and $N \rightarrow O$, wherein said optionally substituted heterocyclyl or heteroaryl ring is optionally substituted with one or more substituents independently selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, $-OC_1-C_4$ alkyl, $-OC_1-C_4$ haloalkyl, halogen, $-OH$, $-NH_2$, $-N(C_1-C_4 \text{ alkyl})(C_1-C_4 \text{ alkyl})$, $-NH(C_1-C_4 \text{ alkyl})$, cyano, nitro, oxo, $-CO_2H$, $-C(O)OC_1-C_4$ alkyl, $-CON(C_1-C_4 \text{ alkyl})(C_1-C_4 \text{ alkyl})$, $-CONH(C_1-C_4 \text{ alkyl})$, $-CONH_2$, $-NHC(O)(C_1-C_4 \text{ alkyl})$, $-C(O)C_1-C_4$ alkyl, $-C(O)C_1-C_4$ haloalkyl, $-OC(O)C_1-C_4$ alkyl, $-OC(O)C_1-C_4$ haloalkyl, $-SO_2(C_1-C_4 \text{ alkyl})$, $-SO_2(C_1-C_4 \text{ haloalkyl})$, $-SO_2NH_2$, $-SO_2NH(C_1-C_4 \text{ alkyl})$, $-NHS(O)_2(C_1-C_4 \text{ alkyl})$, and $-NHS(O)_2(C_1-C_4 \text{ haloalkyl})$, where said C_1-C_4 alkyl is unsubstituted C_1-C_4 alkyl,

R^B is $-CONHR^3$, $-SO_2R^3$, $-CO_2R^3$, $-COC(R^4R^5)R^3$,

wherein R^3 is hydrogen or an optionally substituted C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, C_3-C_7 cycloalkyl, heteroaryl, heterocyclyl, aryl- C_1-C_4 alkyl- or heteroaryl- C_1-C_4 alkyl- group,

where said optionally substituted R^3 group is optionally substituted with one or more substituents independently selected from halogen, $-R^{3a}$, $-OR^{3a}$, $-SR^{3a}$, $-SO_2R^{3c}$

$-\text{NR}^{3a}\text{R}^{3b}$, cyano, nitro, $-\text{COR}^{3c}$, $-\text{CO}_2\text{R}^{3a}$, $-\text{NR}^{3b}\text{COR}^{3a}$, $-\text{CONR}^{3a}\text{R}^{3b}$, $-\text{NR}^{3b}\text{SO}_2\text{R}^{3c}$, and $-\text{SO}_2\text{NR}^{3a}\text{R}^{3b}$,

where R^{3a} is hydrogen or an optionally substituted C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryl, C_3 - C_7 cycloalkyl, heteroaryl, heterocyclyl, aryl- C_1 - C_4 alkyl-,
 5 C_3 - C_7 cycloalkyl- C_1 - C_4 alkyl-, heteroaryl- C_1 - C_4 alkyl-, heterocyclyl- C_1 - C_4 alkyl-,
 aryl- C_2 - C_4 alkenyl-, C_3 - C_7 cycloalkyl- C_2 - C_4 alkenyl-, heteroaryl- C_2 - C_4 alkenyl-,
 heterocyclyl- C_2 - C_4 alkenyl-, aryl- C_2 - C_4 alkynyl-, C_3 - C_7 cycloalkyl- C_2 - C_4 alkynyl-,
 heteroaryl- C_2 - C_4 alkynyl-, or heterocyclyl- C_2 - C_4 alkynyl- group,

R^{3b} is hydrogen or unsubstituted C_1 - C_4 alkyl, and

10 R^{3c} is an optionally substituted C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, aryl,
 C_3 - C_7 cycloalkyl, heteroaryl, heterocyclyl, aryl- C_1 - C_4 alkyl-, C_3 - C_7 cycloalkyl- C_1 - C_4 alkyl-,
 heteroaryl- C_1 - C_4 alkyl-, heterocyclyl- C_1 - C_4 alkyl-, aryl- C_2 - C_4 alkenyl-,
 C_3 - C_7 cycloalkyl- C_2 - C_4 alkenyl-, heteroaryl- C_2 - C_4 alkenyl-, heterocyclyl- C_2 - C_4 alkenyl-,
 aryl- C_2 - C_4 alkynyl-, C_3 - C_7 cycloalkyl- C_2 - C_4 alkynyl-, heteroaryl- C_2 - C_4 alkynyl-, or
 15 heterocyclyl- C_2 - C_4 alkynyl- group,

where each optionally substituted R^{3a} group and R^{3c} group is independently
 optionally substituted with one or more substituents independently selected from
 C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, $-\text{OC}_1$ - C_4 alkyl, $-\text{OC}_1$ - C_4 haloalkyl, halogen, $-\text{OH}$, $-\text{NH}_2$,
 $-\text{N}(\text{C}_1$ - C_4 alkyl)(C_1 - C_4 alkyl), $-\text{NH}(\text{C}_1$ - C_4 alkyl), cyano, nitro, oxo, $-\text{CO}_2\text{H}$,
 20 $-\text{C}(\text{O})\text{OC}_1$ - C_4 alkyl, $-\text{CON}(\text{C}_1$ - C_4 alkyl)(C_1 - C_4 alkyl), $-\text{CONH}(\text{C}_1$ - C_4 alkyl), $-\text{CONH}_2$,
 $-\text{NHC}(\text{O})(\text{C}_1$ - C_4 alkyl), $-\text{C}(\text{O})\text{C}_1$ - C_4 alkyl, $-\text{C}(\text{O})\text{C}_1$ - C_4 haloalkyl, $-\text{OC}(\text{O})\text{C}_1$ - C_4 alkyl,
 $-\text{OC}(\text{O})\text{C}_1$ - C_4 haloalkyl, $-\text{SO}_2(\text{C}_1$ - C_4 alkyl), $-\text{SO}_2(\text{C}_1$ - C_4 haloalkyl), $-\text{SO}_2\text{NH}_2$, $-\text{SO}_2\text{NH}(\text{C}_1$ - C_4 alkyl),
 $-\text{NHS}(\text{O})_2(\text{C}_1$ - C_4 alkyl), and $-\text{NHS}(\text{O})_2(\text{C}_1$ - C_4 haloalkyl), where said
 C_1 - C_4 alkyl is unsubstituted C_1 - C_4 alkyl,

25 or R^{3a} and R^{3b} , together with the nitrogen atom to which they are attached, form an
 optionally substituted heterocycl or heteroaryl ring which optionally contains one or more
 additional heteroatom moieties selected from O, S, SO, SO_2 , N and $\text{N}\rightarrow\text{O}$, wherein said
 optionally substituted heterocycl or heteroaryl ring is optionally substituted with one or
 more substituents independently selected from C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, $-\text{OC}_1$ - C_4 alkyl,
 30 $-\text{OC}_1$ - C_4 haloalkyl, halogen, $-\text{OH}$, $-\text{NH}_2$, $-\text{N}(\text{C}_1$ - C_4 alkyl)(C_1 - C_4 alkyl), $-\text{NH}(\text{C}_1$ - C_4 alkyl),
 cyano, nitro, oxo, $-\text{CO}_2\text{H}$, $-\text{C}(\text{O})\text{OC}_1$ - C_4 alkyl, $-\text{CON}(\text{C}_1$ - C_4 alkyl)(C_1 - C_4 alkyl),
 $-\text{CONH}(\text{C}_1$ - C_4 alkyl), $-\text{CONH}_2$, $-\text{NHC}(\text{O})(\text{C}_1$ - C_4 alkyl), $-\text{C}(\text{O})\text{C}_1$ - C_4 alkyl,
 $-\text{C}(\text{O})\text{C}_1$ - C_4 haloalkyl, $-\text{OC}(\text{O})\text{C}_1$ - C_4 alkyl, $-\text{OC}(\text{O})\text{C}_1$ - C_4 haloalkyl, $-\text{SO}_2(\text{C}_1$ - C_4 alkyl), -

SO₂(C₁-C₄ haloalkyl), -SO₂NH₂, -SO₂NH(C₁-C₄ alkyl), -NHS(O)₂(C₁-C₄ alkyl), and -NHS(O)₂(C₁-C₄ haloalkyl), where said C₁-C₄ alkyl is unsubstituted C₁-C₄ alkyl, and


R⁴ and R⁵ are independently selected from hydrogen and unsubstituted C₁-C₄ alkyl, or R⁴ and R⁵, taken together with the carbon atom to which they are attached,

- 5 represent an optionally substituted 3-6-membered saturated carbocyclic ring, where said optionally substituted 3-6-membered ring is substituted with one or more substituents independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, -OC₁-C₄ alkyl, -OC₁-C₄ haloalkyl, halogen, -OH, -NH₂, -N(C₁-C₄ alkyl)(C₁-C₄ alkyl), -NH(C₁-C₄ alkyl), cyano, nitro, oxo, -CO₂H, -C(O)OC₁-C₄ alkyl, -CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl),
 10 -CONH₂, -NHC(O)(C₁-C₄ alkyl), -C(O)C₁-C₄ alkyl, -C(O)C₁-C₄ haloalkyl, -OC(O)C₁-C₄ alkyl, -OC(O)C₁-C₄ haloalkyl, -SO₂(C₁-C₄ alkyl), -SO₂(C₁-C₄ haloalkyl), -SO₂NH₂, -SO₂NH(C₁-C₄ alkyl), -NHS(O)₂(C₁-C₄ alkyl), and -NHS(O)₂(C₁-C₄ haloalkyl), where said C₁-C₄ alkyl is unsubstituted C₁-C₄ alkyl.,


or a salt, solvate, or physiologically functional derivative thereof.

15

2. A compound according to claim 1, wherein n is 1 or 2.
3. A compound according to claim 1 or claim 2, wherein X is O or NR².
- 20 4. A compound according to claim 1, having the formula:



5. A compound according to claim 1, having the formula:



6. A compound according to claim 1, wherein R^A is $-\text{CONHR}^1$, $-\text{NHCOR}^1$, or $-\text{NHSO}_2\text{R}^1$, where R^1 is C_1 - C_6 alkyl, aryl, heteroaryl, heterocycyl, aryl- C_1 - C_4 alkyl-, heteroaryl- C_1 - C_4 alkyl-, or heterocycyl- C_1 - C_4 alkyl-, wherein said C_1 - C_6 alkyl is optionally substituted with one or more substituents independently selected from $-\text{NH}_2$, $-\text{N}(\text{C}_1\text{-C}_4 \text{ alkyl})(\text{C}_1\text{-C}_4 \text{ alkyl})$, and $-\text{NH}(\text{C}_1\text{-C}_4 \text{ alkyl})$, or said aryl, heteroaryl or heterocycyl or the aryl, heteroaryl or heterocycyl moiety of said aryl- C_1 - C_4 alkyl-, heteroaryl- C_1 - C_4 alkyl-, or heterocycyl- C_1 - C_4 alkyl- is unsubstituted or substituted by one or more substituents independently selected from C_1 - C_4 alkyl, C_1 - C_4 haloalkyl and halogen..
7. A compound according to claim 1, wherein R^B is $-\text{CONHR}^3$ or $-\text{SO}_2\text{R}^3$; where R^3 is aryl or heteroaryl, wherein said aryl or heteroaryl is unsubstituted or substituted by one or more substituents independently selected from C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, halogen, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, aryl, heteroaryl and heterocycyl.
8. A compound according to claim 1, wherein R^A is $-\text{CONHR}^1$, where R^1 is C_1 - C_6 alkyl, aryl, heteroaryl, heterocycyl, aryl- C_1 - C_4 alkyl-, heteroaryl- C_1 - C_4 alkyl-, or heterocycyl- C_1 - C_4 alkyl-, wherein said C_1 - C_6 alkyl is optionally substituted with one or more substituents independently selected from $-\text{NH}_2$, $-\text{N}(\text{C}_1\text{-C}_4 \text{ alkyl})(\text{C}_1\text{-C}_4 \text{ alkyl})$, and $-\text{NH}(\text{C}_1\text{-C}_4 \text{ alkyl})$, or said aryl, heteroaryl or heterocycyl or the aryl, heteroaryl or heterocycyl moiety of said aryl- C_1 - C_4 alkyl-, heteroaryl- C_1 - C_4 alkyl-, or heterocycyl- C_1 - C_4 alkyl- is unsubstituted or substituted by one or more substituents independently selected from C_1 - C_4 alkyl, C_1 - C_4 haloalkyl and halogen..
9. A compound according to claim 1, wherein R^B is $-\text{CONHR}^3$, where R^3 is aryl or heteroaryl, wherein said aryl or heteroaryl is unsubstituted or substituted by one or more

substituents independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, aryl, heteroaryl and heterocycyl.

10. A compound according to claim 1, wherein R^A is -CONHR¹, -NHCOR¹, -NHSO₂R¹,
5 where R¹ is C₁-C₆ alkyl, aryl, heteroaryl, heterocycyl, aryl-C₁-C₄ alkyl-,
heteroaryl-C₁-C₄ alkyl-, or heterocycyl-C₁-C₄ alkyl-, wherein said C₁-C₆ alkyl is optionally
substituted with one or more substituents independently selected from -NH₂,
-N(C₁-C₄ alkyl)(C₁-C₄ alkyl), -NH(C₁-C₄ alkyl), or said aryl, heteroaryl or heterocycyl or the
10 aryl, heteroaryl or heterocycyl moiety of said aryl-C₁-C₄ alkyl-, heteroaryl-C₁-C₄ alkyl-, or
heterocycyl-C₁-C₄ alkyl- is unsubstituted or substituted by one or more substituents
independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl and halogen., and R^B is -CONHR³
or -SO₂NHR³; where R³ is aryl or heteroaryl, wherein said aryl or heteroaryl is
unsubstituted or substituted by one or more substituents independently selected from
15 C₁-C₄ alkyl, C₁-C₄ haloalkyl, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, aryl, heteroaryl and
heterocycyl;
or a salt, solvate, or physiologically functional derivative thereof.

11. A compound according to claim 10, wherein
R¹ is methyl, ethyl, phenyl, benzyl, phenethyl, N,N diethylaminopropyl, N-methyl-
20 piperidiny, piperidiny-ethyl, pyrrolidiny-butyl, morpholino-ethyl, or morpholino-propyl;
and
R³ is substituted phenyl or substituted isoxazolyl, where said phenyl or isoxazolyl is
substituted by one or more substituents independently selected from F, Cl, CF₃, or *tert*-
butyl;
25 or a salt, solvate, or physiologically functional derivative thereof.

12. A compound according to claim 1 wherein
n is 1 or 2;
R^A is -CONHR¹, where R¹ is methyl, ethyl, phenyl, benzyl, phenethyl, N,N
30 diethylaminopropyl, N-methyl-piperidiny, piperidiny-ethyl, pyrrolidiny-butyl,
morpholino-ethyl, or morpholino-propyl;
X is O; and

R^B is $-\text{CONHR}^3$, where R^3 is substituted phenyl or substituted isoxazolyl, where said phenyl or isoxazolyl is substituted by one or more substituents independently selected from F, Cl, CF_3 , or *tert*-butyl;
or a salt, solvate, or physiologically functional derivative thereof.

5

13. A compound according to claim 1 wherein
n is 1;

R^A is $-\text{CONHR}^1$, where R^1 is methyl, ethyl, phenyl, benzyl, phenethyl, N,N diethylaminopropyl, N-methyl-piperidinyl, piperidinyl-ethyl, pyrrolidinyl-butyl,
morpholino-ethyl, or morpholino-propyl;

10

X is O; and

R^B is $-\text{CONHR}^3$, where R^3 is substituted phenyl or substituted isoxazolyl, where said phenyl or isoxazolyl is substituted by one or more substituents independently selected from F, Cl, CF_3 , or *tert*-butyl;

15

or a salt, solvate, or physiologically functional derivative thereof.

14. A pharmaceutical composition, comprising:

a) a therapeutically effective amount of a compound according to claim 1, or a salt, solvate, or a physiologically functional derivative thereof, and

20

b) one or more of pharmaceutically acceptable carriers, diluents and excipients,

c) the composition optionally further comprising an additional agent selected from anti-neoplastic agents, agents which inhibit angiogenesis, or a combination thereof.

15. A method of treating a mammal having a disorder mediated by at least one of
inappropriate TIE-2 kinase, VEGFR-2 kinase, VEGFR-3 kinase or Raf kinase activity

25

comprising administering to said mammal a therapeutically effective amount of a compound according to claim 1, or a salt, solvate, or a physiologically functional derivative thereof.

30 16. A method of treating a mammal having a cancer, comprising administering to said mammal a therapeutically effective amount of a compound according to claim 1, or a salt, solvate, or a physiologically functional derivative thereof,

the method optionally further comprising administering a therapeutically effective amount of at least one additional anti-cancer therapy, for example, wherein the additional anti-cancer therapy is administered before, concomitantly with, or after the administration of the compound according to claim 1, salt, solvate or physiologically functional derivative thereof.

17. A method of treating a mammal having a disease which is characterized by cellular proliferation in the area of disorders associated with neo-vascularization and/or vascular permeability in a mammal, comprising administering to said mammal a therapeutically effective amount of compound according to claim 1, or a salt, solvate, or a physiologically functional derivative thereof.

18. A method of treating a mammal having a disorder mediated by at least one of inappropriate TIE-2 kinase, VEGFR-2 kinase, or VEGFR-3 kinase activity, comprising administering to said mammal therapeutically effective amounts of:

- a) a compound according to claim 1, or a salt, solvate or physiologically functional derivative thereof, and
- b) an agent to inhibit growth factor receptor function,
wherein the agent to inhibit growth factor receptor function is selected from an agent that inhibits the function of platelet derived growth factor receptor, the function of epidermal growth factor receptor, the function of the erbB2 receptor, the function of the erbB4 receptor, the function of a VEGF receptor, and/or the function of the TIE-2 receptor, wherein:
 - i) the agent to inhibit growth factor receptor function inhibits the function of the epidermal growth factor receptor and the erbB2 receptor;
 - ii) the agent to inhibit growth factor receptor function inhibits the function of at least two of the epidermal growth factor receptor, the erbB2 receptor, and the erbB4 receptor; or
 - iii) the agent to inhibit growth factor receptor function inhibits the function of at least one of the VEGF receptor and the TIE-2 receptor.

19. A method of treating a mammal having a disorder characterized by inappropriate angiogenesis, comprising administering to said mammal a therapeutically effective amount of a compound according to claim 1, or a salt, solvate or physiologically functional derivative thereof,
- 5 wherein the inappropriate angiogenesis results from at least one of inappropriate VEGFR-2 kinase, VEGFR-3 kinase, or TIE-2 kinase activity, and
- the method optionally further comprising administering a therapeutically effective amount of a VEGFR2 inhibitor.
- 10 20. The method according to claim 15, wherein the disorder is selected from cancer and diseases afflicting mammals which are characterized by cellular proliferation and being in the area of disorders associated with neo-vascularization and/or vascular permeability. -